InChIKey	NEMGRZFTLSKBAP-LBPRGKRZSA-N
Compound Name	Safinamide
Canonical SMILES	C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	2
Pfam Stratification	Homologous
Avg pChEMBL	7.58
Source	ChEMBL;BindingDB

DrugBank ID	DB06654
Drug Name	Safinamide
CAS Number	133865-89-1
Groups	approved investigational
ATC Codes	N04BD03
Description	Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.

---

Categories: Agents that produce hypertension Agents that reduce seizure threshold Amines Amino Acids Amino Acids, Peptides, and Proteins Anti-Parkinson Drugs Antidepressive Agents BCRP/ABCG2 Inhibitors Benzene Derivatives Benzyl Compounds Central Nervous System Depressants Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 CYP2C19 inhibitors (strength unknown) Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A5 Inhibitors Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Dopamine Agents Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates Monoamine Oxidase B Inhibitors Monoamine Oxidase Inhibitors Nervous System Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome

---

Cross-references: BindingDB: 50078694 ChEBI: 134718 CHEMBL396778 ChemSpider: 116349 Drugs Product Database (DPD): 23038 PubChem:131682 PubChem:347827780 RxCUI: 1922448 Wikipedia: Safinamide ZINC: ZINC000053084692